Stephane Bancel
President and Founding CEO @ Moderna
Boston, United States
Stephane Bancel is a seed investor at Moderna in Boston focused on Software and Wellness. Stephane joined Flagship Ventures in 2013 and focuses on providing strategic counsel and support to portfolio companies. He is President and Founding Chief Executive Officer of Moderna Therapeutics, a Flagship VentureLabs - founded company. He is also executive chairman of the board for portfolio company BG Medicine, Inc.Stephane was previouslyCEO of bioMerieux, a world leader in the diagnostics industry. During his five years leading the company, he accelerated the company's sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. During that time, the company's market capitalization nearly doubled despite the financial crisis. Prior to his time at bioMerieux, Stephane was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis.He holds a Master of Engineering from Ecole Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for Investor Relations in France in 2009 and was ranked #1 CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Stephane Bancel invests in
Stages Stephane Bancel invests in
Countries Stephane Bancel invests in
Round sizes
Round size
- Seed
- $22M–$23M
Investment Focus
Industry
- Software 1 (33%)
- Wellness 1 (33%)
- Health Care 1 (33%)
- Chemical Engineering 1 (33%)
- Professional Services 1 (33%)
Stage
- Seed 1 (33%)
- Series D 1 (33%)
Country
- France 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
L Nutra
|
L-Nutra is a Science, Technology company that specializes in researchers and collaborators are leaders in the field of nutrition. | $47M / Series D / Nov 07, 2023 | |
Zoī
|
Zoī is a science-backed holistic approach for health and wellness, starting with a 360° physical check-up, and leveraging data and behavioral sciences. Zoī provides a one-of-a-kind in-person experience to finally understand own physiology. The company was founded in 2021 and is headquartered in Paris, France. | $21.9M / Seed / Jan 24, 2022 | |
|
Zoī
|
Zoī is a science-backed holistic approach for health and wellness, starting with a 360° physical check-up, and leveraging data and behavioral sciences. Zoī provides a one-of-a-kind in-person experience to finally understand own physiology. The company was founded in 2021 and is headquartered in Paris, France. | $22.6M / Seed / Jan 24, 2022 |
Co-Investors
Brentwood Associates
1 deal together
About Moderna
Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies insidepatient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
Moderna Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Eric Ma
Principal Data Scientist
|
|||
Kenneth Chien
Co-Founder
|
|||
Marcello Damiani
Chief Digital & Operational Excellence Officer
|
|||
John Mendlein
President, Corporate and Product Strategy
|
|||
Noubar Afeyan
Chairman & Co-Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Stephane Bancel invest in?
Stephane Bancel invests primarily in Software, Wellness and Health Care startups, most often at Seed and Series D stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Stephane Bancel's check size?
Stephane Bancel typically joins rounds of $22M–$23M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Stephane Bancel participates in.
When did Stephane Bancel last invest?
The most recent investment recorded for Stephane Bancel closed in Nov 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
